Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 51 to 75 of 1147 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
968 abnormal animal organ formation (GO:0048645) urethra (UBERON:0000057) 2213: Impaired, urethral tube closure
675 increased unsaturated fatty acid biosynthetic process (GO:0006636) unsaturated fatty acid (CHEBI:27208) 1285: Up Regulation, Unsaturated fatty acid
1125 decreased mRNA transcription (GO:0009299) undifferentiated genital tubercle (UBERON:0005876) None
529 increased gene expression (GO:0010467) UDP-glucuronosyltransferase (PR:000024849) 1020: Increased, induction of UDPGT's in liver
747 decreased regulation of binding (GO:0051098) tyrosine-protein kinase JAK3 (PR:000009198) 1715: Inhibition of JAK3
778 decreased protein tyrosine kinase activity (GO:0004713) tyrosine-protein kinase fyna (zebrafish) (PR:Q6EWH2) 1884: Inhibition of Fyna
405 increased tyrosine (CHEBI:18186) 775: Increased, Plasma tyrosine
604 decreased catalytic activity (GO:0003824) type III iodothyronine deiodinase (PR:000006482) 1153: Inhibition, Deiodinase 3
521 decreased catalytic activity (GO:0003824) type II iodothyronine deiodinase (PR:000006481) 1002: Inhibition, Deiodinase 2
526 decreased catalytic activity (GO:0003824) type I iodothyronine deiodinase (PR:000006480) 1009: Inhibition, Deiodinase 1
788 decreased cellular response to type I interferon (GO:0071357) type I interferon receptor complex (GO:0038197) None
833 increased tumor necrosis factor secretion (GO:1990774) tumor necrosis factor alpha (PR:000000134) 1868: Hyperinflammation
623 increased cytokine production (GO:0001816) tumor necrosis factor alpha (PR:000000134) 1224: Non-neuronal production of TNF, Epithelial irritation
828 increased Increased inflammatory response (HP:0012649) tumor necrosis factor alpha (PR:000000134) None
722 disrupted tubulin complex (GO:0045298) 718: Binding, Tubulin
372 increased tubulin binding (GO:0015631) tubulin (PR:000028799) 718: Binding, Tubulin
176 increased triglyceride (CHEBI:17855) 291: Accumulation, Triglyceride
253 increased biosynthetic process (GO:0009058) triglyceride (CHEBI:17855)
246 increased triglyceride biosynthetic process (GO:0019432) triglyceride (CHEBI:17855) 454: Increased, Triglyceride formation
618 increased reflex (GO:0060004) trigeminal nerve (UBERON:0001645) 1223: Trigeminal and/or vagal nerve excitation causes Airway Hyper-responsiveness,Cough, Dyspnea
503 increased binding (GO:0005488) transthyretin (PR:000016801) 957: Binding, Transthyretin in serum
850 increased protease binding (GO:0002020) transmembrane protease serine 2 (human) (PR:O15393) None
848 increased transmembrane protease serine 2 (human) (PR:O15393) None
874 occurrence protease binding (GO:0002020) transmembrane protease serine 2 (PR:000016456) None
876 occurrence membrane fusion (GO:0061025) transmembrane protease serine 2 (PR:000016456) 1738: SARS-CoV-2 cell entry